Caliway Biopharmaceuticals Co., Ltd. Stock

Equities

6919

TW0006919004

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
379 TWD -1.04% Intraday chart for Caliway Biopharmaceuticals Co., Ltd. -0.26% +98.17%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 12.82M 395K Sales 2023 38.93M 1.2M Capitalization 26.6B 820M
Net income 2022 -286M -8.82M Net income 2023 -488M -15.05M EV / Sales 2022 503 x
Net cash position 2022 1.08B 33.38M Net cash position 2023 3.69B 114M EV / Sales 2023 588 x
P/E ratio 2022
-25.1 x
P/E ratio 2023
-48.5 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints CI
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease MT
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease CI
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug MT
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction CI
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug MT
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease CI
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding CI
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study CI
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study MT
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7 CI
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite CI
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index CI
More news
1 day-1.04%
1 week-0.26%
Current month-1.30%
1 month-5.49%
3 months+55.65%
6 months+98.43%
Current year+98.17%
More quotes
1 week
372.00
Extreme 372
385.00
1 month
355.00
Extreme 355
400.50
Current year
187.25
Extreme 187.25
406.00
1 year
140.75
Extreme 140.75
406.00
3 years
55.50
Extreme 55.5
406.00
5 years
55.50
Extreme 55.5
406.00
10 years
55.50
Extreme 55.5
406.00
More quotes
Date Price Change Volume
24-05-10 379 -1.04% 97,493
24-05-09 383 +1.46% 239,838
24-05-08 377.5 -0.40% 288,184
24-05-07 379 -0.26% 178,778
24-05-06 380 0.00% 462,854

End-of-day quote Taipei Exchange, May 09, 2024

More quotes
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW